The European injection pen market is anticipated to grow at a CAGR of 7.4% over the forecast period. The key factors that drive the growth of the market in the region include easy availability of these devices in the region owing to the presence of key players such as Sanofi SA, Novo Nordisk AS, F. Hoffmann-La Roche Ltd. among many others which are pioneers in innovation, design, and manufacture of the injection pen.
Some of the instances of the injection pen provided by the companies include the AllStar Pro pen injector which is a reusable pen injector for the drug delivery to the patient. Further, Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus are connected pens are reusable and include a tiny screen that displays the last dose that is approved in Europe (CE marked) for the use. Hence, this is likely to drive the growth of the European injection pen industry over the forecast period.
A full report of European Injection Pen Market is available at: https://www.omrglobal.com/industry-reports/european-injection-pen-market
The major countries of Europe including the UK, France, Germany, Italy, Spain, and the Rest of Europe support the market growth. Increasing cases of diabetes in these countries has more individuals taking insulin, which could also be self-taken using an insulin pen. As per the Diabetes UK, in 2019, there were almost 3.7 million people who were diagnosed with diabetes in the country; IDF recorded more than 3 million cases of diabetes in France in 2019; as per a 2019 report by the German Diabetes Center (DDZ), more than 7.2% of the population in Germany suffer from diabetes. Thus, this creates a scope for market growth in the major economies of Europe over the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-injection-pen-market
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type, By Disorder Type
- Regions Covered- Europe
- Competitive Landscape- F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, AstraZeneca Plc, Bayer AG, Novo Nordisk A/S, and Sanofi SA
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
European Injection Pen Market – Segmentation
By Type
- Reusable
- Disposable
By Disorder Type
- Autoimmune Disorders
- Hormonal Disorders
- Orphan Diseases
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
